Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Immutep Limited (IMMP) Stock Up +4.00% Today?

Why Is Immutep Limited (IMMP) Stock Up +4.00% Today?

Key Takeaways

  • IMMP shares rose 4.00%, or $0.13, to $3.38 in early Nasdaq trading, building on the prior session's close of $3.25.
  • The primary catalyst was a new company release detailing expanded EFTISARC-NEO Phase II survival data presented at the CTOS 2026 meeting in Seoul.
  • Secondary drivers included the prior day's investor update on the TACTI-004 root cause analysis and a refocused efti development strategy, plus a newly granted U.S. patent.
  • The move was company-specific: no sector-wide or macro development was identified, and the stock remains a thinly traded micro-cap well below its pre-March 2026 levels.
  • News Significance Score: 23/100 — Moderate incremental clinical news met a price move almost exactly in line with the stock's typical daily swing.
  • Traders are watching the 27 November annual general meeting, the December ESMO Immuno-Oncology overall survival update, and the targeted second-half 2027 start of a registration-directed sarcoma trial.
  • Cash of roughly A$48.5 million at 30 September supports a runway the company guides into the first half of calendar 2028.
  • For deeper detail on IMMP Price Targets, Earnings and Forecast, explore Tickeron's dedicated research pages.
  • Readers can also review the curated Trending AI Robots list for live strategies trading this and other names.

Opening Summary

Immutep Limited (IMMP) is a Sydney-based, clinical-stage biotechnology company pioneering therapies built around LAG-3, an immune checkpoint it both stimulates to fight cancer and suppresses to calm autoimmune disease. Its lead cancer asset is eftilagimod alfa ("efti"), while IMP761 is a first-in-class LAG-3 agonist antibody in early autoimmune testing. On Thursday morning, the stock traded at $3.38, up $0.13 or 4.00%, from the previous session's close of $3.25, confirming an upward move. The immediate trigger was the release of new EFTISARC-NEO survival and biomarker analyses presented at the Connective Tissue Oncology Society annual meeting, layered on top of a strategy update issued a day earlier.

New EFTISARC-NEO Data at CTOS 2026

The headline release of the session expanded on an abstract first published on 11 November. In the investigator-initiated Phase II study of efti combined with Keytruda and radiotherapy before surgery in high-risk, resectable soft tissue sarcoma, 38 of 40 enrolled patients underwent surgery and were evaluable. Twelve-month disease-free survival was 81.1%, with an 18-month estimate holding at 81.1% on immature data, alongside 94.1% local recurrence-free survival and 86.2% distant metastasis-free survival after a median 19.1 months of follow-up.

What drove the market reaction was the exploratory analysis. Patients whose post-treatment tumour-infiltrating lymphocyte levels exceeded 310 cells/mm² recorded 95.0% 12-month disease-free survival versus 64.9% for those below that threshold, and patients with treatment-related hyalinisation and fibrosis above 52% recorded 93.8% versus 71.4%. That link between measurable immune activation in the tumour and better outcomes reinforces the case that efti is doing what its mechanism of action predicts — the central argument for a program that has had little to celebrate in 2026. The company said it is preparing a registration-directed trial in neoadjuvant sarcoma targeting a second-half 2027 start, subject to regulatory feedback, manufacturing and partnering.

TACTI-004 Review and the Development Reset

The move also extended a two-week recovery from the year's lows near $2.69. That rebound began with the reset narrative laid out in the 18 November investor update, in which Immutep disclosed that its root cause analysis of the failed Phase III TACTI-004 lung cancer trial had found subtle differences in glycan structures between efti manufactured at 2,000-litre scale and the 200-litre material used in earlier studies. All batches met release specifications, but the differing immune-monitoring profile gave management a coherent explanation for the futility outcome. The company has contracted a new 200-litre batch and narrowed its focus to head and neck squamous cell carcinoma with CPS below 1 and neoadjuvant sarcoma, both backed by FDA designations. The same window brought positive Phase I IMP761 data at ACR Convergence and a fifth U.S. patent covering efti-based combinations.

Market Context and Trading Activity

Turnover has averaged roughly 15,000 shares a session over the past three months, with the heaviest volumes clustered on 6 November, 9 November and 18 November, when daily gains of 24.2%, 13.8% and 2.2% respectively attracted fresh attention. Activity in the opening minutes on Thursday was modest, consistent with a small, retail- and event-driven shareholder base rather than an institutional re-rating. The advance was idiosyncratic: it followed a company-specific scientific release, and no corresponding industry-wide or macro catalyst was evident. Technically, the stock is pressing back toward the $3.50–$3.66 band that capped the November rebound, having bottomed near $2.69 on 5 November; the broader sequence since September remains a deep downtrend from above $7.50.

News Significance Score

The score runs from 0 to 100, where 0 means no meaningful news and a move normal for the stock, and 100 means transformative news paired with an extreme, rare price move. IMMP earns 23 out of 100.

The verified news was moderate in weight: the 81.1% survival figure had already been disclosed on 11 November, so Thursday's increment was biomarker detail and trial-pathway clarity on a secondary endpoint of a 40-patient study — meaningful for sentiment, not decisive for valuation. The price move was equally unremarkable: at 4.00% it was essentially identical to the stock's average absolute daily move of about 4.0% over the last 60 sessions, and 21 of those sessions produced moves of equal or greater size. Weak news and a routine swing combine into a low score.

What Comes Next for IMMP

The near-term calendar is dense. Immutep holds its annual general meeting on 27 November, where it has said it will present the outcome of the TACTI-004 root cause analysis — the single largest outstanding question for investors. Final overall survival data from the head and neck cancer program is expected at ESMO Immuno-Oncology in December, and multiple ascending dose results for IMP761 are guided for the first half of 2027. Analyst coverage remains constructive but sparse, with a Moderate Buy consensus and wide dispersion in published targets. The principal risks are familiar for a micro-cap developer: a high chance that the root cause analysis proves inconclusive, manufacturing and regulatory delays pushing the sarcoma trial beyond 2027, the need to partner or raise capital before the guided runway into the first half of 2028 is exhausted, and the low liquidity that can exaggerate moves in either direction.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are highlighted in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the list offers a practical starting point for matching a system to your own approach. Reviewing the current leaders is a simple way to see which strategies are working in this tape.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IMMP

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


IMMP's RSI Oscillator ascends from oversold territory

The RSI Oscillator for IMMP moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 23 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMMP as a result. In 65 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for IMMP just turned positive on October 20, 2026. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.

Following a +7.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMP advanced for three days, in 208 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 45 cases where IMMP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

IMMP broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMMP entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. IMMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.999) is normal, around the industry mean (3.596). P/E Ratio (-0.310) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (443.347).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of anti-cancer therapeutics

Industry Biotechnology

Industry
Biotechnology
Address
264 George Street
Phone
+61 283157003
Employees
51
Web
https://www.immutep.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.